AXL Inhibition Extinguishes Primitive JAK2 Mutated Myeloproliferative Neoplasm Progenitor Cells
Abstract. Myeloproliferative neoplasms (MPN) are clonal stem cell associated disorders inclusive of chronic myeloid leukemia (CML), Polycythaemia vera (PV), myelofibrosis (MF), and essential thrombocythemia (ET). They are characterized by increased production of myeloid cells with minimal effects on...
Main Authors: | Stella Pearson, Rognvald Blance, Tim C.P. Somervaille, Anthony D. Whetton, Andrew Pierce |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-06-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/HS9.0000000000000233 |
Similar Items
-
Identification of curaxin as a potential new therapeutic for JAK2 V617F mutant patients.
by: Stella Pearson, et al.
Published: (2023-01-01) -
Mouse models of myeloproliferative neoplasms: JAK of all grades
by: Juan Li, et al.
Published: (2011-05-01) -
Combination of curaxin and tyrosine kinase inhibitors display enhanced killing of primitive Chronic Myeloid Leukaemia cells.
by: Stella Pearson, et al.
Published: (2022-01-01) -
Modification of the histone landscape with JAK inhibition in myeloproliferative neoplasms
by: Greenfield, G, et al.
Published: (2020) -
Modification of the Histone Landscape with JAK Inhibition in Myeloproliferative Neoplasms
by: Graeme Greenfield, et al.
Published: (2020-09-01)